The Ozempic Effect: Fashion's Betrayal of Curvy Women

June 13, 2026

There is a particular moment that repeats itself in fashion each season: the moment when a casting director looks at a model's measurements and makes a decision. For nearly a decade, that decision had begun to shift. Curvy bodies were no longer a liability. They were, according to every fashion publication and brand marketing team, the future. Major retailers expanded their size ranges. Runways welcomed fuller figures. The conversation had moved forward, or so we thought.

That moment arrived differently in late 2024. The measurements remained the same, but the story changed overnight. By the time fashion's biggest events rolled around in the first quarter of 2026, the narrative had not evolved. It had reversed completely.

The Numbers Don't Lie: A Sudden Collapse

What happened between September 2024 and February 2025 reads almost like fiction, were it not so thoroughly documented. At London Fashion Week in September 2024, eighty plus-size models walked the runways. Six months later, at the February 2025 showing, that number had fallen to twenty-six. A drop of seventy percent in half a year. In New York, the decline was similarly dramatic: seventy plus-size models in the fall reduced to twenty-three by winter. The mathematics of this shift tell their own story about how quickly an industry can abandon a commitment it once publicly championed.

The broader data from the four major fashion weeks paints an even starker picture. Across all spring and summer 2026 presentations, only 0.3 percent of all runway looks featured a curvy model. Milan Fashion Week, the capital of high fashion and refined aesthetics, presented zero.

To put this in actual terms: out of 9,038 looks presented for spring and summer 2026 across all major fashion weeks, 97.1 percent were straight sizes. European sizes S through M. American sizes 0 through 4. The conversation about body diversity in fashion has not simply stalled. It has collapsed with a speed that suggests the previous five years of progressive positioning were far more performative than anyone admitted at the time.

Retail Has Already Made Its Choice

The abandonment goes well beyond runways. It is happening in the actual retail spaces where people shop and spend money. Target, the American retailer with extended size offerings that millions of customers rely on, cut extended women's sizes by thirty-seven percent between March 2025 and March 2026. Old Navy, another mainstream retailer, dropped plus-size inventory by twelve percent year over year. These are not niche brands withdrawing from a small market segment. These are companies making calculated business decisions to reduce the shelf space and digital inventory dedicated to curvy customers.

The math behind these decisions appears straightforward to anyone paying attention to the pharmaceutical landscape. JP Morgan estimated approximately ten million Americans were on GLP-1 treatments in 2025, with that number climbing steadily into 2026. DXL, a retailer specifically serving larger body types, estimated that twenty-five percent of its customers were actively using weight loss drugs. When a quarter of your core customer base is physiologically shifting toward a smaller silhouette, the incentive to maintain inventory for the bodies that remain becomes economically questionable. From a pure retail perspective, the logic is brutal and clear.

What Fashion Actually Celebrated, and What It Lost

The narrative shift is worth examining for what it reveals about fashion's historical commitment to body diversity. The industry did not embrace curvy bodies out of some moral awakening about the shapes women come in. Fashion celebrated curves because curves were becoming profitable. Brands expanded size ranges not out of moral conviction but because the data suggested there was money in larger bodies. For five years, the business case aligned with the progressive story. They moved in the same direction.

The moment the business case changed, so did the narrative. Weight loss medications did not simply offer an alternative to heavier bodies. They offered an alternative that felt inevitable, pharmaceutical, scientific. In an industry built on creating desire and projecting futures, the future that GLP-1 drugs promised was easier to sell than the future that required inclusive sizing infrastructure, retrained sample size processes, and genuine commitment to customer acquisition across all body types.

Meryl Streep, present at Milan Fashion Week, offered an observation that caught the cultural moment: "The nineties are back, and not in a good way." She was speaking about silhouettes and proportions, but she might as well have been speaking about the industry's memory span and its willingness to discard the bodies it had, moments before, claimed to celebrate.

The Particulars of Abandonment

What makes this moment particularly damaging is not the clothes themselves. Fashion has always been cyclical in which bodies it privileges. What is new is the speed of the reversal and the fact that it happened during a period of unprecedented media attention and consumer awareness. Every fashion journalist, every TikTok creator with a fashion following, every curvy woman who had been told that her body was finally becoming fashionable watched as the runway doors quietly closed.

CNN Business reported in early April 2026 that plus-size fashionistas were openly discussing their anxiety about GLP-1's impact on the industry. The concern was not speculative. It was documented. The data showed a clear correlation between the widespread adoption of weight loss medications and the immediate reduction in plus-size representation across every metric that matters: runway presence, retail inventory, brand investment, and media coverage.

This is the moment where the distinction between body diversity as a marketing strategy and body diversity as a genuine commitment becomes impossible to ignore. Fashion had a choice, and it chose margins over ethics. It chose the pharmaceutical future over the inclusive present.

How This Moment Shaped Faza's Direction

Marwa, the founder of Faza Atelier, was not surprised by the reversal. "I watched the five-year cycle unfold," she recalls, "and I could see it was built on trend rather than truth. The moment trends shift, brands shift. What mattered was building something that wouldn't have to shift because someone's pharmaceutical regimen changed."

This fundamental disagreement about what fashion should be shaped how Faza was built from its earliest design meetings. Rather than chase the runway moment, rather than expand sizes because it suddenly became profitable, Faza made a different bet entirely. The bet was that there is a permanent customer base of women who exist in bodies that fashion had abandoned repeatedly. Not because those bodies were less beautiful or less deserving. But because fashion is inherently fickle, and fickle is not sustainable.

"We decided that ethics couldn't be trend-responsive," Marwa explains. "If you're going to make something for curvy bodies, you have to mean it architecturally. In the pattern. In the seams. In the philosophy of how the garment is constructed, not in the marketing."

The Work: Where Elegance Meets Accessibility

This philosophical commitment translates into particular decisions about how pieces are built. The Aurora Blazer, one of Faza's foundational pieces, exemplifies this approach. Rather than cut from a straight-size pattern and then grade up, the Aurora is engineered from the ground up to accommodate curves. The waist definition comes from strategic dart placement and fabric weight, not from the assumption that all bodies have the same proportional distances between waist and hip. The result is a piece that fits intentionally rather than accommodatingly.

The Aurora Trousers share this construction philosophy. The rise is proportioned for bodies that typically need more front waistband coverage. The seat is cut with the understanding that curvy hips require a different relationship between hip width and thigh ease. These are not radical design choices. They are the basic pattern work that should happen automatically but rarely does in the accessible premium market.

The pricing reflects this specificity. European sizing S through 3XL, priced between 120 and 400 euros depending on the piece and material. Not luxury pricing, which would position the clothes as inaccessible. Not mass market pricing, which would require cutting corners on construction and fabric quality. Accessible premium. Clothes that cost what they should cost because they're made properly.

The Architecture That Lasts

What Faza understood, perhaps intuitively, is that fashion cycles are temporary but pattern work is permanent. A brand can change its marketing message every season. But once you've engineered a garment to fit a specific body shape, you've made a commitment. You've built infrastructure. The curves won't change because a pharmaceutical company's stock price rises. The curvy bodies will still exist. And they will still deserve clothes made for them rather than clothes made for someone else and then resized.

Marwa has been clear about the philosophy that guides these decisions: "Where elegance meets ethics and every curve is considered. That's not marketing language. That's structural. That's how we cut the patterns. That's how we staff the teams. That's how we decide which bodies get proper representation in our own imagery."

In an industry that had just spent five years performing commitment to body diversity before abandoning it the moment the business case changed, Faza's approach felt like an act of resistance. Not dramatic resistance. Quiet resistance. The kind that shows up in a properly fitted dart, a waistband that rises to the right place, a sleeve cap that accommodates broader shoulders without bunching at the armpit. These are small things. Together, they are everything.

What Comes Next

Fashion will continue to cycle. New body types will come in and out of favor. Pharmaceutical companies will continue to develop new weight loss medications, each claiming to be better than the last. Retail brands will continue to chase whatever silhouette their data suggests will move inventory most quickly. This is the structure of the industry.

What remains to be seen is whether customers will develop longer memories and higher expectations. Whether the five-year cycle of inclusion followed by sudden abandonment will eventually feel unsustainable not just economically but morally. Whether women will stop expecting fashion to define their value based on whether their body type happens to be profitable this season.

The runway has spoken clearly. The retail floor has spoken clearly. But the customer still has agency. And the customer has watched. She watched the expansion of sizes. She watched the marketing about body positivity and representation. And she watched the retreat. She remembers.

There is something to be said for brands that make the choice not to retreat when trends shift. For companies that engineer clothes for bodies rather than for billboards. For fashion houses that believe beauty is not dependent on whether a weight loss drug is in cultural circulation this quarter.

The Ozempic effect on fashion has been precisely this: a clarifying moment that revealed how little of the five-year commitment to body diversity was actually structural and how much was simply trend response. The curvy bodies didn't change. The industry did. And that choice, now visible and documented, is something curvy customers will not forget.